TXMD · TherapeuticsMD, Inc.
$2.06
-0.01 (-0.48%)
At close · Jul 28
View the 10-Q filed May 12, 2026
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed May 12, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three months ended March 31, 2026)
“For the three months ended March 31, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$23.84M
Shares
11.57M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2023-07-11 | New | Pharmaceuticals | $5,000,000 | $1,149,998 | 06b |
| 2022-11-14 | New | Pharmaceuticals | $7,000,000 | $7,000,000 | 06b |
| 2022-10-17 | New | Pharmaceuticals | $7,000,000 | $7,000,000 | 06b |
| 2022-08-16 | New | Pharmaceuticals | $15,000,000 | $15,000,000 | 06b |
| 2020-08-14 | New | Pharmaceuticals | $7,500,000 | $7,500,000 | 06b |
Showing 1–5 of 5 filings